ABSTRACT
Objectives The COVID-19 pandemic profoundly affected healthcare systems and patients. There is a pressing need to comprehend the collateral effects of the pandemic on noncommunicable diseases. Here we examined the impact of the COVID-19 pandemic on shortterm cancer survival in the United Kingdom (UK). We hypothesised that short-term survival from nine cancers would be reduced during the pandemic, particularly cancers that benefit from screening and early detection (e.g., breast and colorectal cancer).
Design Population-based cohort study.
Setting Electronic health records from UK primary care Clinical Practice Research Datalink (CPRD) GOLD database.
Participants There were 12,259,744 eligible patients aged ≥18 years with ≥one year of prior history identified from January 2000 to December 2021.
Main outcome measures We estimated age-standardised incidence rates (IR) and short-term (one- and two-year) survival of several common cancers (breast, colorectal, head and neck, liver, lung, oesophagus, pancreatic, prostate, and stomach cancer) from 2000 to 2019 (in five-year strata) compared to 2020 to 2021 using the Kaplan-Meier method.
Results Apart from pancreatic cancer, IRs decreased for all cancers in 2020 and recovered to different extents in 2021. Short-term survival improved for most cancers between 2000 to 2019, but then declined for those diagnosed in 2020 to 2021.This was most pronounced for colorectal cancer, with one-year survival falling from 79.3% [95% confidence interval: 78.5%-80.1%] in 2015 to 2019 to 76.3% [74.6%-78.1%] for those diagnosed in 2020 to 2021.
Conclusion Short-term survival for many cancers was impacted by the management of the COVID-19 pandemic in the UK. This decline was most prominent for colorectal cancer, with reductions in survivorship equivalent to returning to mortality seen in the first decade of the 2000s. These results illustrate the need for an immediate and well-funded investment in resolving the current backlog in cancer screening and diagnostic procedures in the UK National Health Service to improve patient outcomes.
Competing Interest Statement
DPAs department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPAs department. ARS has received honoraria from Janssen, Astellas, Ipsen and Bayer. All other authors declare no conflicts of interest.
Funding Statement
This study was funded by the European Health Data & Evidence Network (EHDEN) and the Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence (OPTIMA) initiative which has received funding from the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement No 806968 and No. 101034347 respectively. IMI2 receives support from the European Unions Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. The views communicated within are those of OPTIMA and EHDEN. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. DPA receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship. DPAs group received partial support from the Oxford NIHR Biomedical Research Centre. FXAJ is funded by Fundacion Cientifica AECC (LABAE18025AVIL); Plan Estatal de I+D+I of the Instituto de Salud Carlos III (FIS PI15/02047 and FIS PI18/0844). Fondo Europeo de Desarrollo Regional (FEDER), A Way to Build Europe, and Funded by the European Union NextGenerationEU Transformation and Resilience Recovery Plan. Spanish government. AWR would like to thank Professor Ismail Gogenur and Dr Mikail Gogenur for discussions regarding development of the colorectal cancer phenotyping used in this study. The study funders had no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The independent scientific advisory committee for Medicine and Healthcare products Regulatory Agency database research gave ethical approval for this work (protocol number 22_001843).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint senior authors
nicola.barclay{at}ndorms.ox.ac.uk
theresa.burkard{at}ndorms.ox.ac.uk
edward.burn{at}ndorms.ox.ac.uk
antonella.delmestri{at}ndorms.ox.ac.uk
amiquel.hj23.ics{at}gencat.cat
asieh.golozar{at}odysseusinc.com
cguarnera{at}santpau.cat
faviles{at}clinic.cat
waiyi.man{at}ndorms.ox.ac.uk
arosello{at}iconcologia.net
anwr{at}regionsjaelland.dk
cheryl.tan{at}ndorms.ox.ac.uk
il.tietzova{at}gmail.com
communication{at}optima-oncology.eu
danielle.newby{at}ndorms.ox.ac.uk
Data Availability
This study is based in part on data from the Clinical Practice Research Datalink (CPRD) obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. Patient- level data used in this study was obtained through an approved application to the CPRD (application number 22_001843) and is only available following an approval process to safeguard the confidentiality of patient data. Details on how to apply for data access can be found at https://cprd.com/data-access.
